Lung transplant list withdrawal in a liver transplant patient thanks to elexacaftor-tezacaftor-ivacaftor: a case report

• Hauptverfasser: Arianna Traunero (VerfasserIn), Anna Galletti (VerfasserIn), Sergio Ghirardo (VerfasserIn), Egidio Barbi (VerfasserIn), Massimo Maschio (VerfasserIn)
• Format: Buch
• Veröffentlicht: BMC, 2024-07-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Background Elexacaftor-tezacaftor-ivacaftor (ETI) is a transmembrane conductance regulator modulator that significantly improves lung function in patients affected by cystic fibrosis (CF). This triple drug is currently not indicated in liver transplant patients, as clinical trials including...